Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Antiviral Drugs

This information is currently being revised for the 2018-2019 influenza season. Note: The Food and Drug Administration (FDA) approved a new influenza antiviral drug, baloxavir marboxil (trade name Xofluza®), on October 24, 2018. Content on this website is being updated to reflect the most recent guidance. More information about baloxavir marboxil [594 KB, 13 pages] is available.

Information for Health Care Professionals

The information on this page should be considered current for the 2017-2018 influenza season for clinical practice regarding the use of influenza antiviral medications. Also see the current summary of recommendations available at Influenza Antiviral Medications: Summary for Clinicians and a list of related references at Antiviral Guide References.

Links on this page contain excerpts from Antiviral Agents for the Treatment and Chemoprophylaxis of Influenza – Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Antiviral Agents for the Treatment and Chemoprophylaxis of Influenza – Recommendations of the Advisory Committee on Immunization Practices (ACIP)
available as PDF [1 MB, 28 pages]

Additional Information for Health Care Professionals

Information for the Public

TOP